Quarterly ResultMay 14, 2026, 04:03 PM
Dare Bioscience Ovaprene Phase 3 Positive DSMB; First Product Revenue Soon
AI Summary
Dare Bioscience reported its Q1 2026 financial results and provided significant business updates, including a second positive DSMB review of interim data from its Ovaprene Phase 3 clinical trial. The company anticipates the commencement of DARE to PLAY dispensing and the commercial launch of Flora Sync LF5 in Summer 2026, with first direct product revenue expected in June 2026. For Q1 2026, revenue was approximately $0.2 million, and the net loss was $3.0 million, an improvement from the prior year.
Key Highlights
- Ovaprene Phase 3 trial received a second positive DSMB review of interim safety and efficacy data.
- DARE to PLAY dispensing is anticipated to commence in Summer 2026.
- Flora Sync LF5 (DARE to RESTORE) commercial launch expected in June 2026, marking first product revenue.
- Q1 2026 revenue was approximately $0.2 million, up from $25,427 in Q1 2025.
- Net loss for Q1 2026 was approximately $3.0 million, compared to $4.4 million in Q1 2025.
- Cash and cash equivalents were $18.5 million as of March 31, 2026.
- Working capital was approximately $0.5 million as of March 31, 2026.
- DARE-HPV is advancing into a Phase 2 clinical study in May 2026 with ARPA-H funding.